Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News  >  Companies  >  All News

News : Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

ELOXX PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/27/2017 | 03:56pm CEST

Item 5.02 Departure of Directors of Certain Officers; Election of Directors;

          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers



On December 26, 2017, the Board of Directors (the "Board") of Eloxx Pharmaceuticals, Inc. (the "Company") appointed Robert E. Ward to serve as Chief Executive Officer of the Company, effective as of December 26, 2017. In connection with his appointment, Mr. Ward was elected as Chairman of the Board effective as of December 26, 2017. Mr. Ward succeeds Dr. Silvia Noiman as Chief Executive Officer of the Company and Dr. Robert Heft as Chairman of the Board. Dr. Noiman and Dr. Heft each stepped down from their respective positions effective as of December 26, 2017. Dr. Noiman will continue her service as a member of the Board. Dr. Heft has resigned from the Board.

Mr. Ward, age 60, served as the Chief Executive Officer and President at Radius Health, Inc. from December 16, 2013 to July 16, 2017. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca from 2011 to 2013. He has held a series of progressive management and executive roles with established companies such as NPS Pharmaceuticals, Schering-Plough (Merck), Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward has been a Director of Akari Therapeutics, Plc since October 14, 2016. He served as a Director of Radius Health, Inc. from December 2013 until July 16, 2017. Mr. Ward serves as a Director of the Massachusetts High Technology Council. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara, an M.S. in Management from the New Jersey Institute of Technology and an M.A. in Immunology from The Johns Hopkins University School of Medicine.

Except as described in the employment agreement (the "Employment Agreement") entered into by the Company and Mr. Ward, effective December 26, 2017 (the "Effective Date"), there is no arrangement or understanding between Mr. Ward and any other person pursuant to which Mr. Ward was selected as an officer. There are no existing or currently proposed transactions to which the Company or any of its subsidiaries is a party and in which Mr. Ward has a direct or indirect material interest. There are no family relationships between Mr. Ward and any of the directors or officers of the Company or any of its subsidiaries.

Pursuant to the terms of his Employment Agreement, Mr. Ward will receive a base salary of $450,000 and is eligible to receive an annual performance-based bonus with a target value equal to fifty percent (50%) of his base salary (the "Annual Bonus"). Mr. Ward is eligible to participate in the Company's benefit programs as made generally available to other senior executives.

Mr. Ward received an inducement award in the form of an option to purchase 22,427 shares of the Company's common stock on the Effective Date with an exercise price per share equal to $8.00, and an award of restricted stock units for 22,427 shares of the Company's common stock (collectively the "Performance Option Awards"). Subject to his continued service through the vesting date, Mr. Ward's Performance Option Awards will vest and become immediately exercisable upon the date that marks the first successful completion of a Phase-2B study with respect to any indication.

In addition, Mr. Ward received an inducement award in the form of an option to purchase 640,785 shares of the Company's common stock with an exercise price per share equal to $8.00, and an award of restricted stock units for 640,785 shares of the Company's common stock (collectively the "Time-Vesting Awards"). Subject to his continued service through the vesting date, 1/3 of Mr. Ward's Time-Vesting Awards will vest and become immediately exercisable on the first anniversary of the Effective Date, with an additional 1/12 of his Time-Vesting Awards vesting on each quarterly anniversary of the Effective Date, provided that vesting of the Time-Vesting Awards shall be subject to acceleration following the achievement of certain milestones.

Pursuant to the terms of the Employment Agreement, upon a termination by the Company without cause or by Mr. Ward for good reason, Mr. Ward will be entitled to (1) continued payments of his base salary for 18 months, (2) payments for COBRA coverage at applicable rates for 12 months, (3) any Annual Bonus earned but unpaid for the year immediately prior to his termination date, (4) a pro-rata portion of the Annual Bonus, to which he would otherwise have been entitled, based on achievement of performance goals as determined by the Board in good faith, (5) accelerated vesting of 25% his unvested shares subject to all stock options, restricted stock units and other equity awards, and (6) an additional 9 months vesting credit for any unvested stock options. If Mr. Ward's employment is terminated by the Company without cause or by Mr. Ward for good reason within 24 months following a Change in Control (as defined in the Employment Agreement), he will be entitled to (1) continued payments of his base salary for 24 months, (2) payments for COBRA coverage at applicable rates for 18 months, (3) any Annual Bonus earned but unpaid for the year immediately prior to his termination date, (4) payment of his full Annual Bonus, to which he would otherwise have been entitled, (5) accelerated vesting of all of his unvested shares subject to all stock options, restricted stock units and other equity awards, and (6) an additional 12 months vesting credit for any unvested stock options.

The foregoing descriptions of the terms of the Employment Agreement do not purport to be a complete description and are qualified in their entirety by reference to the Employment Agreement filed as Exhibits 10.1 to this Current Report Form 8-K.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal

          Year.



On December 20, 2017, following the consummation of the previously announced merger of Eloxx Pharmaceuticals Ltd., an Israeli company ("Eloxx") and Sevion Sub Ltd., an Israeli company and a wholly-owned subsidiary of the Company (f/k/a Sevion Therapeutics, Inc.), with Eloxx surviving the merger as a wholly-owned subsidiary of the Company, the bylaws of the Company were amended and restated in their entirety.

A copy of the Amended and Restated Bylaws of the Company is filed as Exhibit 3.2 to this Current Report on Form 8-K, and is incorporated by reference herein.

Item 7.01 Regulation FD.



On December 27, 2017, the Company issued a press release relating to the appointment of Mr. Ward as Chairman of the Board and Chief Executive Officer. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01 of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit
  No.                                     Description

  3.2           Amended and Restated Bylaws of Eloxx Pharmaceuticals, Inc.

  10.1          Employment Agreement, dated as of December 26, 2017, between Eloxx
              Pharmaceuticals, Inc. and Robert E. Ward.

  99.1          Press Release, dated December 27, 2017.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
05:07aCongress eases post-crisis bank rules in victory for Trump
RE
05:07aSmall banks trump Wall Street on Dodd-Frank rewrite
RE
05:07aPPG INDUSTRIES : Gets New Deadline For Filing Quarterly Report
AQ
05:06aGENERAL CABLE : Responds to Speculation Regarding Alleged Investigation
BU
05:05aARABTEC : subsidiary wins contract in Egypt for $42.7M
AQ
05:02aCBRE : 16 acres on Las Vegas Strip expected to fetch over $540 million
AQ
05:02aThe Business Model Transition To Value-Based Reimbursement – OPEN MINDS’ Ken Carr Keynotes 2018 West Virginia Behavioral Healthcare Providers Association Annual Conference
GL
05:01aOTONOMO : Announces The Consent Management Hub
BU
05:00aSTANBIC : bank committed to improving Uganda’s future
AQ
05:00aGLOBAL CRM ANALYTICS MARKET : Strategic Assessment of Evolving Technology, Trends and Next Generation Industry Analysis by 2021: Global Cloud Service Brokerage Market: Analysis by Focusing on Growth Strategies and Upcoming Trends, End Users, Industry Verticals, Shares, Technology, Application Along with Top Key players like Oracle, Zoho Corporation Pvt. Ltd., Salesforce.com, Inc., Google, KAPTURE, HubSpot, Inc., Infor, SEDONA
AQ
Latest news "Companies"
Advertisement